Compass Capital Management Inc. Buys 145,018 Shares of Boston Scientific Corporation $BSX

Compass Capital Management Inc. raised its stake in Boston Scientific Corporation (NYSE:BSX) by 16.9% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,004,548 shares of the medical equipment provider’s stock after acquiring an additional 145,018 shares during the quarter. Boston Scientific comprises 2.8% of Compass Capital Management Inc.’s holdings, making the stock its 21st largest position. Compass Capital Management Inc. owned 0.07% of Boston Scientific worth $43,849,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently made changes to their positions in BSX. SVB Wealth LLC grew its position in shares of Boston Scientific by 457.7% in the third quarter. SVB Wealth LLC now owns 31,868 shares of the medical equipment provider’s stock valued at $1,391,000 after purchasing an additional 26,154 shares during the last quarter. Russell Investments Group Ltd. lifted its holdings in Boston Scientific by 10.8% during the 3rd quarter. Russell Investments Group Ltd. now owns 3,207,330 shares of the medical equipment provider’s stock worth $140,024,000 after purchasing an additional 311,634 shares during the last quarter. Eurizon Capital SGR S.p.A. lifted its holdings in Boston Scientific by 31.9% during the 3rd quarter. Eurizon Capital SGR S.p.A. now owns 1,596,301 shares of the medical equipment provider’s stock worth $69,766,000 after purchasing an additional 386,008 shares during the last quarter. PBU The Pension Fund of Early Childhood & Youth Educators boosted its stake in Boston Scientific by 18.8% in the 3rd quarter. PBU The Pension Fund of Early Childhood & Youth Educators now owns 263,677 shares of the medical equipment provider’s stock valued at $11,510,000 after purchasing an additional 41,713 shares during the period. Finally, Werba Rubin Papier Wealth Management bought a new stake in Boston Scientific in the 3rd quarter valued at $239,000. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Stock Up 0.3%

NYSE BSX opened at $44.33 on Friday. The business has a fifty day moving average price of $44.00 and a two-hundred day moving average price of $54.50. The stock has a market capitalization of $64.25 billion, a PE ratio of 18.78, a PEG ratio of 1.31 and a beta of 0.60. Boston Scientific Corporation has a fifty-two week low of $39.57 and a fifty-two week high of $104.61. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.36 and a quick ratio of 0.81.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, October 28th. The medical equipment provider reported $0.73 EPS for the quarter, hitting analysts’ consensus estimates of $0.73. Boston Scientific had a return on equity of 18.61% and a net margin of 16.62%. The company had revenue of $5.14 billion during the quarter, compared to analysts’ expectations of $5.09 billion. During the same quarter in the previous year, the firm earned $0.75 EPS. Boston Scientific’s revenue was up 1.4% on a year-over-year basis. Equities analysts expect that Boston Scientific Corporation will post 3.17 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the company. Wells Fargo & Company lowered their price objective on Boston Scientific from $48.00 to $45.00 and set an “equal weight” rating on the stock in a research report on Thursday, October 29th. Mizuho set a $50.00 target price on shares of Boston Scientific in a research report on Thursday, October 29th. Stifel Nicolaus decreased their price target on shares of Boston Scientific from $60.00 to $55.00 and set a “buy” rating on the stock in a research note on Monday, October 26th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Boston Scientific in a research report on Friday, October 2nd. Finally, Leerink Partners dropped their price objective on shares of Boston Scientific from $55.00 to $50.00 and set an “outperform” rating for the company in a research note on Thursday, October 29th. One research analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating, eight have assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $61.43.

About Boston Scientific

Boston Scientific is a medical technology company that develops, manufactures and markets devices used in minimally invasive procedures across a range of medical specialties. Founded in 1979, the company is headquartered in Marlborough, Massachusetts. Its products support areas including cardiovascular care, endoscopy, urology and neuromodulation. They include catheter-based devices and therapies for conditions affecting the heart and blood vessels, as well as devices used in diagnostic and therapeutic procedures involving the digestive and urinary systems.